Septerna (NASDAQ:SEPN) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Septerna (NASDAQ:SEPN) in a report released on Tuesday,Benzinga reports. They currently have a $50.00 price target on the stock.

Several other equities research analysts have also recently issued reports on the stock. Wells Fargo & Company began coverage on shares of Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $43.00 target price on the stock. TD Cowen started coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. assumed coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective for the company.

Septerna Trading Down 13.6 %

NASDAQ SEPN opened at $11.38 on Tuesday. The firm has a 50 day moving average price of $20.17. Septerna has a 1-year low of $11.27 and a 1-year high of $28.99.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SEPN. Vanguard Group Inc. acquired a new stake in Septerna during the fourth quarter worth about $22,557,000. Corebridge Financial Inc. purchased a new stake in shares of Septerna in the 4th quarter valued at approximately $212,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Septerna during the 4th quarter worth approximately $3,197,000. PNC Financial Services Group Inc. purchased a new stake in shares of Septerna during the 4th quarter valued at approximately $61,000. Finally, Bank of New York Mellon Corp acquired a new position in Septerna in the fourth quarter valued at approximately $872,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.